.
Pharmaxis Limited (ASX:PXS) has reported a net loss of $19.5 million, or 13 per cent, in the half year to December 2011.
Revenue from ordinary activities was up 41 per cent, but profit from ordinary activities after tax was down 13 per cent.
Sales in the drug Aridol, Pharmaxis' first commercial product, were up, thanks to US and South Korean customer demand. The drug is a lung function test designed to help doctors diagnose and manage asthma.
Company director Alan Robertson said in the report the decrease in interest income was attributable to the decrease in cash, and cash equivalents, available for investment.
The company won’t pay a dividend.
Pharmaxis reported a net loss of $45.7 million for the six months to June.
- Forums
- ASX - By Stock
- SNT
- News: Pharmaxis reports 13% loss
News: Pharmaxis reports 13% loss
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.2¢ |
Change
-0.003(6.67%) |
Mkt cap ! $57.67M |
Open | High | Low | Value | Volume |
4.5¢ | 4.5¢ | 4.2¢ | $57.82K | 1.360M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 368290 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 133896 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 368290 | 0.042 |
2 | 1000000 | 0.041 |
7 | 670000 | 0.040 |
1 | 52631 | 0.038 |
2 | 600000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 133896 | 4 |
0.044 | 1110965 | 2 |
0.045 | 622319 | 2 |
0.046 | 100000 | 1 |
0.047 | 20000 | 1 |
Last trade - 15.43pm 08/10/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |